熱門資訊> 正文

Revolution Pharmaceuticals和Summit Therapeutics就癌症治疗达成协议

2025-06-30 22:15

Revolution Medicines (NASDAQ:RVMD) and Summit Therapeutics (NASDAQ:SMMT) announced a clinical partnership to assess each of Revolution's RAS(ON) inhibitors with Summit's bispecific antibody, ivonescimab, in various solid tumor settings.
The partnership will assess Revolution's multi-selective inhibitor daraxonrasib, G12D-selective inhibitor zoldonrasib and G12C-selective inhibitor elironrasib with ivonescimab.

More on Summit Therapeutics, Revolution Medicines

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History
Explaining Summit's Fall Despite Positive Data In EGFR-Positive Lung Cancer
Summit Therapeutics: Market Overreaction Creates Opportunity
Revolution Medicines dips 5%, gets $2B flexible funding
Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。